Position on National Security Commission on Emerging Biotechnology Final Report: Charting the Future of Biotechnology
The Federation of American Scientists supports the National Security Commission on Emerging Biotechnology’s Final Report and the Recommendations contained within it.
Charting the Future of Biotechnology delivers 49 recommendations to foster the growth of the biotechnology and biomanufacturing sector within the U.S. bioeconomy. Implementing the recommendations outlined in this report will strengthen the U.S. bioeconomy by establishing a unified national strategy that fosters innovation in biotechnology, ensures our continued global competitiveness, and delivers significant economic and societal benefits to the nation.
FAS is particularly excited by these recommendations:
- 1.1a: Establishment of a National Biotechnology Coordination Office
- 2.2a-d: Economic levers to promote scale-up and innovations coming to market
- 2.4a: Biotechnology infrastructure and data to be classified as “critical infrastructure”
- 3.1a: Department of Defense to consult with stakeholders to define principles for ethical use of biotechnology
- 4.3a-c: Centers for Biotechnology
- 5.1a through 5.3b: Biotechnology workforce for the future
- 6.1a-e: Strengthen global U.S. biotechnology efforts through global policy
These recommendations have the potential to address key challenges within the U.S. bioeconomy, including the lack of a coordinated strategy, commercialization barriers, workforce shortages, and supply chain vulnerabilities.
“FAS applauds the NSCEB’s deep investigation of unlocking U.S.-led biotechnology in the Fourth Industrial Revolution. We look forward to bringing FAS’s unique and effective approach of policy entrepreneurship to realize the promise of these capabilities while reducing the risks of misuse,” said Yong-Bee Lim, Associate Director of Global Risk at the Federation of American Scientists.
“The National Commission on Emerging Biotechnology report developed 50 recommendations to address the major challenges currently facing the U.S. bioeconomy: a lack of strategy and coordination across the federal government, difficulties in scaling biotechnology innovations, and the need for a trained workforce for the future. These recommendations aim to de-risk the biotechnology sector, thereby enabling private sector investment in critical biotechnology and biomanufacturing initiatives. Ultimately, these efforts will foster continued growth, secure the U.S. bioeconomy, and lead to the creation of new jobs and further economic growth.”” said Nazish Jeffery, Bioeconomy Policy Manager at the Federation of American Scientists. “It will be important to continue advocating, refining, and adding additional recommendations in order to realize the full value that this report offers.”
For more information contact Nazish Jeffery, FAS Bioeconomy Policy Manager, njeffery@fas.org.
To better understand what might drive the way we live, learn, and work in 2050, we’re asking the community to share their expertise and thoughts about how key factors like research and development infrastructure and automation will shape the trajectory of the ecosystem.
Recognizing the power of the national transportation infrastructure expert community and its distributed expertise, ARPA-I took a different route that would instead bring the full collective brainpower to bear around appropriately ambitious ideas.
NIH needs to seriously invest in both the infrastructure and funding to undertake rigorous nutrition clinical trials, so that we can rapidly improve food and make progress on obesity.
Modernizing ClinicalTrials.gov will empower patients, oncologists, and others to better understand what trials are available, where they are available, and their up-to-date eligibility criteria, using standardized search categories to make them more easily discoverable.